Chris Magryta, M.D., commonly known as Dr. M, has been studying the effects of human lifestyle decisions on disease risk and longevity for decades. He has decided to take this information and specifically hone down the focus to mothers and their children with a desire to improve longevity and health outcomes. How do we set up a mother for ideal health and prepare a child for a great start at life? How do we then provide the best environment for a child to succeed mentally and physically throughout childhood? These are many other questions will be addressed in the Women and Children podcast. So sit back, download a few podcasts, and let us learn together today!
All content for Dr. M's Women and Children First Podcast is the property of Dr. Chris Magryta, "Dr. M" and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Chris Magryta, M.D., commonly known as Dr. M, has been studying the effects of human lifestyle decisions on disease risk and longevity for decades. He has decided to take this information and specifically hone down the focus to mothers and their children with a desire to improve longevity and health outcomes. How do we set up a mother for ideal health and prepare a child for a great start at life? How do we then provide the best environment for a child to succeed mentally and physically throughout childhood? These are many other questions will be addressed in the Women and Children podcast. So sit back, download a few podcasts, and let us learn together today!
Literature Review
1) An exciting phase three trial with the CETP inhibitor Obicetrapib has shown serious promise for ASCVD and Alzheimer's Disease (AD). "In BROADWAY, a pre-specified AD sub-study was designed to assess plasma AD biomarkers in patients enrolled in the BROADWAY trial and evaluated the effects of longer duration of therapy (12 months) with a prespecified population of ApoE3/4 or 4/4 carriers. The sub-study included 1727 patients, including 367 ApoE4 carriers. The primary outcome measure was p-tau217 absolute and percent change over 12 months. Additional outcome measures included neurofilament light chain (“NFL”), glial fibrillary acidic protein (“GFAP”), p-tau181, and Aβ42/40 ratio absolute and percent change over 12 months. NewAmsterdam observed statistically significant lower absolute changes in p-tau217 compared to placebo over 12 months in both the full ITT population (p<0.002) and in ApoE4 carriers (p=0.0215)." (NAMS)
Obicetrapib has shown significant LDL and Lp(a) lowering effects as well in early trials. I will be watching this discovery closely as it may be a game changer for these diseases. "In the BROADWAY trial, more than 2,500 participants with established heart disease or genetic high cholesterol were given either Obicetrapib or a placebo, in addition to their regular cholesterol medications. After 12 weeks, those on Obicetrapib had dropped their LDL cholesterol by 32.6 per cent and Lp(a) by 33.5 per cent on average – many achieved guideline-recommended targets for the first time." (Sci Tech Daily) The drop in Lp(a) is the profound result as this is a massive risk factor for ASCVD and to date is not moveable by statins and most used meds.
2) GLP1 drugs and risk for macular degeneration?... and more
Dr. M
Dr. M's Women and Children First Podcast
Chris Magryta, M.D., commonly known as Dr. M, has been studying the effects of human lifestyle decisions on disease risk and longevity for decades. He has decided to take this information and specifically hone down the focus to mothers and their children with a desire to improve longevity and health outcomes. How do we set up a mother for ideal health and prepare a child for a great start at life? How do we then provide the best environment for a child to succeed mentally and physically throughout childhood? These are many other questions will be addressed in the Women and Children podcast. So sit back, download a few podcasts, and let us learn together today!
